A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants

NCT02152332 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-54861911-Therapeutic Dose
DRUG: JNJ-54861911 - Supratherapeutic Dose
DRUG: JNJ-54861911-Matched Placebo
DRUG: Moxifloxacin
DRUG: Moxifloxacin Matched Placebo

Sponsor

Janssen Research & Development, LLC